People
Quentis Therapeutics Names Jeanne Magram, Ph.D. as Chief Scientific Officer
21 May 2018 - - New York, New York-based biotechnology company Quentis Therapeutics Inc. has appointed Jeanne Magram, Ph.D. as chief scientific officer, the company said.
Magram has over 20 years of drug discovery and development experience. She was the founding chief scientific officer of Northern Biologics, a Toronto Canada based biotechnology company. Prior to Northern Biologics, she served as the site head for Pfizer's Centers for Therapeutic Innovation, New York.
Previously, Magram was vice president, immunology and inflammation research at Boehringer Ingelheim, overseeing a department committed to drug discovery to address unmet medical needs in autoimmune disease.
Prior to Boehringer Ingelheim, she was an associate director of G protein-coupled receptor drug discovery at OSI Pharmaceuticals. She also previously spent over five years at Hoffmann-La Roche focused on using model systems to understand the pathophysiology of disease and to identify new therapies.
Magram completed her postdoctoral training in the laboratory of Nobel Laureate J. Michael Bishop, M.D. at the University of California, San Francisco School of Medicine and obtained her Ph.D. in the laboratory of Franklin Costantini, Ph.D. in the Department of Genetics and Development at Columbia University Irving Medical Center.
Privately held Quentis Therapeutics is pursuing first-in-class endoplasmic reticulum stress response-targeted therapies to address serious diseases such as cancer.
The company is pioneering the use of ER stress response modulators to boost the immune system's ability to fight cancer and to help more cancer patients benefit from immunotherapy. Its lead program is a first-in-class, small molecule, IRE1α inhibitor.
Login
Username:

Password: